1. Home
  2. VNRX

VNRX

VolitionRX Limited

Logo VolitionRX Limited

Health Care

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Founded: N/A Country:
United States
United States
Employees: 110 City: HENDERSON
Market Cap: 50.6M IPO Year: N/A
Target Price: $3.75 AVG Volume (30 days): 116.1K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.50 EPS Growth: N/A
52 Week Low/High: $0.55 - $2.10 Next Earning Date: 05-08-2024
Revenue: $775,302 Revenue Growth: 153.04%
Revenue Growth (this year): 405.61% Revenue Growth (next year): 305.66%

Share on Social Networks: